The More Life Company (STU:20MP) Total Debt per Share: €0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is The More Life Company Total Debt per Share?

The More Life Company STU:20MP -2.70% Total Debt per Share is €0.00 as of Mar. 2026. The stock has 3 warning signs investors should review.

€0.00 (As of Mar. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. The More Life Company's Total Debt Per Share for the quarter that ended in Mar. 2026 was €0.00.


The More Life Company Total Debt per Share Historical Data

* Premium members only.

The historical data trend for The More Life Company's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The More Life Company Total Debt per Share Chart

The More Life Company Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Debt per Share
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

The More Life Company Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

The More Life Company Total Debt per Share Calculation

The More Life Company's Total Debt Per Share for the fiscal year that ended in Mar. 2026 is calculated as:

The More Life Company's Total Debt Per Share for the quarter that ended in Mar. 2026 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of €0.00 mean?
The More Life Company (STU:20MP) has a Total Debt per Share of €0.00 as of Mar. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on The More Life Company and its competitors.
Is The More Life Company's Total Debt per Share too high?
The More Life Company's current Total Debt per Share is €0.00.
How does The More Life Company's Total Debt per Share compare to ZTS?
The More Life Company's Total Debt per Share of €0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Drug Manufacturers company?
A good Total Debt per Share depends on the Drug Manufacturers industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on The More Life Company and its competitors. The More Life Company's current Total Debt per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The More Life Company stock overvalued right now?
The More Life Company (STU:20MP) has a current Total Debt per Share of €0.00. The current Total Debt per Share is €0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For The More Life Company (STU:20MP), the current Total Debt per Share is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

The More Life Company Business Description

Other Exchanges MVMDF:USAMVMD:Canada
Address 260 Edgeley Boulevard, Unit 4, Vaughan, ON, CAN, L6K 3Y4
Mountain Valley MD Holdings Inc is a Canada-based company. The firm, along with its subsidiaries, is engaged in implementing its Quicksome oral delivery technologies across a variety of molecules in nutraceutical, vaccine, and pharmaceutical drug applications. The company actively invests in and collaborates on pioneering biotechnologies that have the potential to revolutionize the human health and wellness landscape, drive sustainable increases in plant yields and agricultural farming practices, and broadly support animal husbandry health. The Company is a biotech company focused on advancing solutions to optimize human, animal, and plant health.